Nektar Therapeutics, and we continue to build on the success with significant progress in 2026. In October 2023, we began the first phase 2 study of our novel Treg biologic Respag Aldesleukin, in ...

A new study showed that among psoriasis therapies, biologics and a stepwise regimen combining phototherapy with biologics provided the greatest efficacy and quality-of-life gains, although ...

The company’s strategic focus sharpened on ZYNLONTA, with a reiteration of peak revenue targets and an expanded discussion of market opportunities in second-line and indolent lymphoma indications. R&D ...

Innovative glycobiology platform aimed at enhancing the efficacy, safety, and scalability of next-generation antibody therapeutics across multiple disease areas ...

The audited financial statements for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K contain an audit opinion from the Company’s independent registered public ...

G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...

Capricor Therapeutics’ deramiocel was rejected in July 2025, potentially caught between Nicole Verdun, a former top biologics regulator at the FDA, and Vinay Prasad, director of the Center for ...

The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

Therapeutic antibodies are among the most widely used biologic medicines, yet detecting subtle structural differences in these complex proteins remains challenging. Researchers in Japan have ...

MDLifespan founder joins Dr. Pamela W. Smith and leading faculty to advance physician education on toxin burden & ...

Researchers have used mouse models to study how cocaine addiction alters the brain, illuminating why relapse is common as ...

While a higher proportion of physicians are prescribing biologics, ‘the growth rate has been faster for APCs,’ one of the study authors said.